Perspectives on Injectable HIV Pre-Exposure Prophylaxis: A Qualitative Study of Health Care Providers in the United States.

Jacob Bleasdale, Meghan McCole, Kenneth Cole, Amy Hequembourg, Gene D Morse, Sarahmona M Przybyla
Author Information
  1. Jacob Bleasdale: Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, Florida, USA. ORCID
  2. Meghan McCole: Department of Community Health and Health Behavior, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA.
  3. Kenneth Cole: Department of Community Health and Health Behavior, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA.
  4. Amy Hequembourg: School of Nursing, University at Buffalo, Buffalo, New York, USA.
  5. Gene D Morse: Department of Community Health and Health Behavior, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA.
  6. Sarahmona M Przybyla: Department of Community Health and Health Behavior, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA.

Abstract

The introduction of injectable HIV pre-exposure prophylaxis (PrEP) has the potential to significantly change the biomedical HIV prevention landscape. However, effective implementation will require health care providers to adopt, prescribe, and administer injectable PrEP within clinical settings. This study qualitatively examined challenges and benefit of injectable PrEP implementation from the perspective of health care providers. From April to August 2022, we conducted 19 in-depth interviews with current PrEP-prescribing health care providers in New York State, including 3 physician assistants, 5 physicians, and 11 nurse practitioners. Interviews were audio-recorded, transcribed verbatim, and thematically analyzed to report semantic-level themes regarding injectable PrEP implementation. More than half of participants (61%) were aware of injectable PrEP; only 21% had experience prescribing it. Qualitative findings highlighted five themes. Three themes represented implementation challenges, including speculative concerns about side effects, appointment compliance, and practical and logistical considerations. The remaining two themes described benefits of injectable PrEP relative to oral PrEP, which included greater convenience and enhanced privacy. Findings from this qualitative study make significant applied contributions to the sparse knowledge on health care provider perspectives of injectable PrEP post-US Food and Drug Administration approval and their concerns and considerations regarding implementation in real-world clinical settings.

Keywords

References

  1. AIDS Patient Care STDS. 2018 Dec;32(12):511-518 [PMID: 31021175]
  2. Arch Sex Behav. 2018 Oct;47(7):2101-2107 [PMID: 28929260]
  3. HIV Med. 2023 Jun;24(6):653-663 [PMID: 36468218]
  4. AIDS Behav. 2017 May;21(5):1229-1235 [PMID: 26143247]
  5. AIDS Care. 2022 Nov;34(11):1435-1442 [PMID: 35109734]
  6. AIDS Res Hum Retroviruses. 2022 Nov;38(11):856-862 [PMID: 35972754]
  7. Lancet HIV. 2023 Dec;10(12):e767-e778 [PMID: 37952550]
  8. AIDS Behav. 2022 Jan;26(1):88-95 [PMID: 34142274]
  9. AIDS Behav. 2023 Nov;27(11):3755-3766 [PMID: 37351685]
  10. Lancet HIV. 2020 Jul;7(7):e472-e481 [PMID: 32497491]
  11. AIDS Patient Care STDS. 2023 Jun;37(6):306-315 [PMID: 37195728]
  12. J Infect Dis. 2022 May 16;225(10):1741-1749 [PMID: 35301540]
  13. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):46-53 [PMID: 29847480]
  14. Health Promot Pract. 2022 Nov;23(6):912-915 [PMID: 35713273]
  15. Clin Infect Dis. 2019 Jan 18;68(3):501-504 [PMID: 29982304]
  16. J Assoc Nurses AIDS Care. 2022 Jan-Feb 01;33(1):89-97 [PMID: 34086636]
  17. Curr HIV/AIDS Rep. 2020 Dec;17(6):579-588 [PMID: 32965576]
  18. Adv Ther. 2020 May;37(5):1778-1811 [PMID: 32232664]
  19. AIDS Patient Care STDS. 2022 Jul;36(7):254-262 [PMID: 35727647]
  20. HIV Clin Trials. 2018 Aug;19(4):129-138 [PMID: 30445896]
  21. AIDS Patient Care STDS. 2019 Nov;33(11):482-491 [PMID: 31603712]
  22. J Clin Nurs. 2019 Jan;28(1-2):351-361 [PMID: 30230068]
  23. N Engl J Med. 2021 Aug 12;385(7):595-608 [PMID: 34379922]
  24. AIDS Patient Care STDS. 2022 Nov;36(11):431-442 [PMID: 36367995]
  25. Health Equity. 2022 Jan 20;6(1):27-31 [PMID: 35112043]
  26. AIDS Care. 2019 Oct;31(10):1207-1213 [PMID: 30822101]
  27. AIDS Behav. 2023 Aug;27(8):2606-2616 [PMID: 36670210]
  28. BMC Nurs. 2020 Dec 9;19(1):117 [PMID: 33292201]
  29. AIDS Res Hum Retroviruses. 2018 Oct;34(10):849-856 [PMID: 30229684]
  30. PLoS One. 2017 Feb 21;12(2):e0172354 [PMID: 28222118]
  31. PLoS One. 2018 Jul 19;13(7):e0200296 [PMID: 30024903]
  32. PLoS One. 2017 Aug 21;12(8):e0183521 [PMID: 28827821]
  33. Lancet. 2022 May 7;399(10337):1779-1789 [PMID: 35378077]
  34. J Int AIDS Soc. 2023 Jul;26 Suppl 2:e26107 [PMID: 37439057]
  35. AIDS Behav. 2020 May;24(5):1452-1462 [PMID: 31654172]
  36. Open Forum Infect Dis. 2019 Oct 1;6(10): [PMID: 31412131]
  37. AIDS Behav. 2021 Mar;25(3):667-678 [PMID: 32910351]
  38. AIDS Patient Care STDS. 2023 Oct;37(10):495-503 [PMID: 37862078]
  39. AIDS Behav. 2017 May;21(5):1336-1349 [PMID: 27770215]
  40. J Int AIDS Soc. 2023 Jul;26 Suppl 2:e26094 [PMID: 37439050]
  41. Curr Opin HIV AIDS. 2015 Jul;10(4):290-5 [PMID: 26049956]
  42. PLoS One. 2018 Dec 28;13(12):e0209484 [PMID: 30592756]
  43. AIDS Care. 2021 Jun;33(6):706-711 [PMID: 32838546]
  44. Lancet HIV. 2023 Dec;10(12):e756-e757 [PMID: 37952552]
  45. AIDS Behav. 2018 Nov;22(11):3540-3549 [PMID: 29290075]

Grants

  1. T32 AA025877/NIAAA NIH HHS
  2. UL1 TR001412/NCATS NIH HHS

MeSH Term

Humans
Pre-Exposure Prophylaxis
HIV Infections
Qualitative Research
Health Personnel
Anti-HIV Agents
Female
Male
United States
Injections
Adult
Interviews as Topic
Attitude of Health Personnel
Middle Aged
New York

Chemicals

Anti-HIV Agents

Word Cloud

Created with Highcharts 10.0.0injectablePrEPimplementationhealthcareHIVprovidersthemespre-exposureprophylaxispreventionclinicalsettingsstudychallengesincludingregardingQualitativeconcernsconsiderationsqualitativeintroductionpotentialsignificantlychangebiomedicallandscapeHowevereffectivewillrequireadoptprescribeadministerwithinqualitativelyexaminedbenefitperspectiveAprilAugust2022conducted19in-depthinterviewscurrentPrEP-prescribingNewYorkState3physicianassistants5physicians11nursepractitionersInterviewsaudio-recordedtranscribedverbatimthematicallyanalyzedreportsemantic-levelhalfparticipants61%aware21%experienceprescribingfindingshighlightedfiveThreerepresentedspeculativesideeffectsappointmentcompliancepracticallogisticalremainingtwodescribedbenefitsrelativeoralincludedgreaterconvenienceenhancedprivacyFindingsmakesignificantappliedcontributionssparseknowledgeproviderperspectivespost-USFoodDrugAdministrationapprovalreal-worldPerspectivesInjectablePre-ExposureProphylaxis:StudyHealthCareProvidersUnitedStatesresearch

Similar Articles

Cited By (1)